Abstract
Leber's hereditary optic neuropathy (LHON) is a mitochondrial disorder leading to severe visual impairment or even blindness by death of retinal ganglion cells (RGCs). The primary cause of the disease is usually a mutation of the mitochondrial genome (mtDNA) causing a single amino acid exchange in one of the mtDNA-encoded subunits of NADH:ubiquinone oxidoreductase, the first complex of the electron transport chain. It was thus obvious to accuse neuronal energy depletion as the most probable mediator of neuronal death. The group of Valerio Carelli and other authors have nicely shown that energy depletion shapes the cell fate in a LHON cybrid cell model. However, the cybrids used were osteosarcoma cells, which do not fully model neuronal energy metabolism. Although complex I mutations may cause oxidative stress, a potential pathogenetic role of the latter was less taken into focus. The hypothesis of bioenergetic failure does not provide a simple explanation for the relatively late disease onset and for the incomplete penetrance, which differs remarkably between genders. It is assumed that other genetic and environmental factors are needed in addition to the ‘primary LHON mutations’ to elicit RGC death. Relevant nuclear modifier genes have not been identified so far. The review discusses the unresolved problems of a pathogenetic hypothesis based on ATP decline and/or ROS-induced apoptosis in RGCs.
Keywords: mtDNA, LHON, OXPHOS, cybrid, PTP, ROS, ATP, RGCs, Oxidative Stress, Parkinsons Disease, Amyotrophic Lateral Sclerosis, Alzheimer's Disease
Current Genomics
Title: LHON: Mitochondrial Mutations and More
Volume: 12 Issue: 1
Author(s): E. Kirches
Affiliation:
Keywords: mtDNA, LHON, OXPHOS, cybrid, PTP, ROS, ATP, RGCs, Oxidative Stress, Parkinsons Disease, Amyotrophic Lateral Sclerosis, Alzheimer's Disease
Abstract: Leber's hereditary optic neuropathy (LHON) is a mitochondrial disorder leading to severe visual impairment or even blindness by death of retinal ganglion cells (RGCs). The primary cause of the disease is usually a mutation of the mitochondrial genome (mtDNA) causing a single amino acid exchange in one of the mtDNA-encoded subunits of NADH:ubiquinone oxidoreductase, the first complex of the electron transport chain. It was thus obvious to accuse neuronal energy depletion as the most probable mediator of neuronal death. The group of Valerio Carelli and other authors have nicely shown that energy depletion shapes the cell fate in a LHON cybrid cell model. However, the cybrids used were osteosarcoma cells, which do not fully model neuronal energy metabolism. Although complex I mutations may cause oxidative stress, a potential pathogenetic role of the latter was less taken into focus. The hypothesis of bioenergetic failure does not provide a simple explanation for the relatively late disease onset and for the incomplete penetrance, which differs remarkably between genders. It is assumed that other genetic and environmental factors are needed in addition to the ‘primary LHON mutations’ to elicit RGC death. Relevant nuclear modifier genes have not been identified so far. The review discusses the unresolved problems of a pathogenetic hypothesis based on ATP decline and/or ROS-induced apoptosis in RGCs.
Export Options
About this article
Cite this article as:
Kirches E., LHON: Mitochondrial Mutations and More, Current Genomics 2011; 12 (1) . https://dx.doi.org/10.2174/138920211794520150
DOI https://dx.doi.org/10.2174/138920211794520150 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review on Chitosan in Drug Delivery for Treatment of Neurological and
Psychiatric Disorders
Current Pharmaceutical Biotechnology Amyloid-β Inhibits PDGFβ Receptor Activation and Prevents PDGF-BBInduced Neuroprotection
Current Alzheimer Research PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets The NK-1 Receptor is Involved in the Antitumoural Action of L-733,060 and in the Mitogenic Action of Substance P on Human Pancreatic Cancer Cell Lines
Letters in Drug Design & Discovery Modular Nanotransporters for Targeted Intracellular Delivery of Drugs: Folate Receptors as Potential Targets
Current Pharmaceutical Design Netrin and DCC: Axon Guidance Regulators at the Intersection of Nervous System Development and Cancer
Current Drug Targets Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment
Current Cancer Therapy Reviews Conformational Diseases and Structure-Toxicity Relationships: Lessons from Prion-Derived Peptides
Current Protein & Peptide Science Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals
Current Drug Delivery Alzheimer Disease: What Role for Leptin and Insulin?
Central Nervous System Agents in Medicinal Chemistry Induced Pluripotent Stem Cell-Based Studies of Parkinson's Disease: Challenges and Promises
CNS & Neurological Disorders - Drug Targets Role of the Sex Hormone Estrogen in the Prevention of Lipid Disorder
Current Medicinal Chemistry Therapeutic Trials in Human Transmissible Spongiform Encephalopathies: Recent Advances and Problems to Address
Infectious Disorders - Drug Targets The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets New Spirocyclic Hydroxamic Acids as Effective Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Glycogen Synthase Kinase-3 (GSK3) in Psychiatric Diseases and Therapeutic Interventions
Current Drug Targets P53 Gene Therapy Sensitizes Resistant Breast Cancer Cells to Doxorubicin Chemotherapy
Drug Delivery Letters Recent Syntheses and Biological Activity of Lentiginosine and its Analogues
Current Topics in Medicinal Chemistry Vascular Endothelial Growth Factor Receptors [VEGFR] as Target in Breast Cancer Treatment: Current Status in Preclinical and Clinical Studies and Future Directions
Current Topics in Medicinal Chemistry Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer
Current Drug Targets